Australia Inflation Cools in May, But Core CPI Keeps RBA Rate Hike Risks Alive 
Japan Manufacturing Growth Accelerates in June as Orders Surge Despite Iran War Cost Pressures 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Malaysia Central Bank Moves to Support Ringgit Amid Foreign Fund Outflows 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Bessent Says U.S. Must Strengthen Supply Chains and Economic Security 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Wall Street Slides as AI Stocks Tumble Following South Korea Tech Sell-Off 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
South Korea Remains MSCI Emerging Market Despite Reform Progress 
Oil Prices Slip as Iran Sanctions Relief and Hormuz Shipping Recovery Ease Supply Concerns 
Samsung Electronics’s executive chairman, Lee Jae Yong, has been holding meetings with leaders of the leading biopharmaceutical and biotechnology companies to forge joint ventures or enter into partnership deals.
The Samsung Electronics chief reportedly met up with global executives of some leading brands in the biotech and biopharma industry, including Johnson & Johnson’s chief executive officer, Joaquin Duato; Biogen’s chief, Christopher Viehbacher; Bristol Myers Squibb’s CEO, Giovanni Caforio; Kevin Ali, Organon’s CEO; and Noubar Afeyan of Flagship Pioneering.
Lee held meetings with them during his recent trip to the United States. Korea Joongang Daily reported that the Samsung leader has a goal of securing partnership agreements with them as he is seeing the biopharma and biotech fields as the company’s new growth drivers.
The Samsung chairman also commented during his trip, "The starting point is not important, but bold and persistent challenges set victory apart from defeat. Let us continue the success story of chips with bio."
In any case, Lee Jae Yong is trying to get contracts for the company’s CMDO arm, Samsung Biologics, which is currently the largest contract manufacturing and development organization in the world based on production capacity.
While it is a latecomer in this market, Samsung Biologics is doing fairly well since it was first established in 2011. Samsung Electronics owns 31.22% of shares in its affiliate CMDO firm.
"The bio-industry is a field with high barriers to entry, requiring not only production technology and R&D capabilities but also trust and reputation building for long-term collaboration,” The Korea Times quoted Samsung as saying in a statement regarding the chairman's move to seek collaborations with US bio companies. “Lee's wide global network is expected to serve as a lever for Samsung's bio business to expand collaboration with big pharmaceutical companies and create future growth opportunities."
